Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride

Journal of Urology

Volumn 165, Issue 1, 2001, Pages 289-293

  Shibata, Yasuhiro ^a   Fukabori, Yoshitatsu ^a   Ito, Kazuto ^a   Suzuki, Kazuhiro ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Chlormadinone acetate; Dogs; Finasteride; Prostatic hyperplasia

Indexed keywords

CHLORMADINONE ACETATE; FINASTERIDE;

ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOG; DRUG EFFECT; HISTOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RECEPTOR BINDING;

EID: 0034747693     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-200101000-00081     Document Type: Article

References (29)

1. Natural history, evaluation, and nonsurgical management of benign prostatic hyperplasia
2. Hormonal therapy in the management of benign prostatic hyperplasia
3. Expression and degradation of rat androgen receptor following castration, testosterone replacement and antiandrogens administration: Analysis by Western blot and immunohistochemistry
4. Effects of oral administration of chlormadinone acetate on canine prostatic hypertrophy
5. Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy
6. Clinical evaluation of chlormadinone acetate (CMA) in benign prostatic hypertrophy
7. Clinical effects of chlormadinone acetate (CMA) on human benign prostatic hypertrophy comparative study with hexestrol by a double blind trial
8. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community based study. CUSP Investigators. Community based study of Proscar
9. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group
10. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: A primary care study. Primary Care Investigator Study Group
11. Histological evaluation of benign prostatic hyperplasia treated by longterm administration of chlormadinone acetate (CMA)
12. Long-term effects of finasteride on prostate tissue composition
13. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: Effect of 5-alpha reductase inhibitors
14. Estimation of canine prostatic volume: Nomogram based on prostatic cubic volume
15. Studies on plasma 5 alpha-dihydrotestosterone
16. The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: Ultrastructural cytochemistry by a new technique
17. Effects of chronic oral administration of a selective 5 alpha-reductase inhibitor, finasteride, on the dog prostate
18. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride
19. Evidence for atrophy and apoptosis in the prostates of men given finasteride
20. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat
21. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5 alpha-reductase
22. Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition
23. Morphology of rat prostatic lobes and seminal vesicles after long-term estrogen treatment
24. The evidence of estrogen production in the prostate
25. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia
26. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
27. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia
28. Does doxazosin affect prostatic growth?
29. Clinical efficacy and reduction effect on prostatic volume of chlormadinone acetate combined with tamsulosin hydrochloride in benign prostatic hyperplasia patients insufficiently treated with tamsulosin hydrochloride only